Cancer Therapy Seen to Protect Blood-brain Barrier, Ease MS in Mouse Model

Cancer Therapy Seen to Protect Blood-brain Barrier, Ease MS in Mouse Model

Publication date: Jan 12, 2021

Imatinib, a cancer treatment, stopped an injury response mechanism of the central nervous system (CNS) from activating, damage to which is a hallmark of multiple sclerosis (MS), an early study reported.

Treatment with imatinib lessened immune cell infiltration and eased disease progression in mouse models of MS. Study researchers suggested that treatments with a similar mechanism of action might be of benefit in neurological diseases marked by BBB disruption.

In a previous study in a rat EAE model, the researchers showed that treatment with imatinib, approved to treat certain types of leukemia (a cancer that begins in white blood cells) and other cancers, preserved BBB integrity and ameliorated clinical symptoms of the disease.

Concepts Keywords
Blood Leukemia
Brain Common injury
Central Nervous System MS
Endothelial Multiple sclerosis
Genetic Branches of biology
Imatinib Nervous system
Karolinska Institute Neurology
Leukemia Central nervous system
Membrane Circulatory system
Mice Animal testing
Multiple Sclerosis Experimental autoimmune encephalomyelitis
Nature Multiple sclerosis
Neurological Diseases Imatinib
PDGF Neuroinflammation
PDGFR Leukemia
Platelet Blood–brain barrier
Remission Alpha
Scientific Reports
Spinal Cord
White Blood Cells


Type Source Name
disease MESH Cancer
drug DRUGBANK Imatinib
disease MESH multiple sclerosis
disease MESH disease progression
disease MESH experimental autoimmune encephalomyelitis
disease MESH leukemia

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *